List of Excipients in Branded Drug CORTIFOAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	CETYL ALCOHOL
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	ETHYLENE DISTEARAMIDE
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	ISOBUTANE
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	METHYLPARABEN
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	PROPANE
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	PROPYLENE GLYCOL
Viatris Specialty LLC	CORTIFOAM	hydrocortisone acetate	0037-6830	PROPYLPARABEN

CORTIFOAM Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

CORTIFOAM is a hydrocortisone acetate rectal foam for short-term treatment of ulcerative proctitis. Its commercial opportunity is based less on molecule innovation than on delivery performance: rapid rectal deployment, reproducible foam retention, low leakage, acceptable mucosal tolerability, and a manufacturing process that can support a generic or reformulated product.

The product’s main development risks are excipient compatibility, foam stability, actuator performance, container closure integrity, and clinical equivalence. A differentiated product could target improved retention, lower irritation, reduced environmental impact from propellants, or a more convenient single-use delivery system.

What is CORTIFOAM and how does its formulation work?

CORTIFOAM contains hydrocortisone acetate, a locally acting corticosteroid, in a rectal aerosol foam dosage form. The historical FDA labeling identifies the product as a 10% hydrocortisone acetate rectal aerosol intended for ulcerative proctitis [1].

The formulation is designed to create a low-density foam that can be administered through a rectal applicator. The dosage form must spread across inflamed rectal mucosa without requiring a large liquid volume. The foam vehicle also has to remain sufficiently cohesive during administration while breaking down after contact with the mucosal surface.

What excipients are used in CORTIFOAM?

Public labeling identifies the principal inactive ingredients as:

Excipient or component	Likely formulation role
Cetyl alcohol	Foam structure, emolliency, viscosity control
Stearyl alcohol	Foam structure and consistency
Emulsifying wax	Emulsion stabilization and body
Polysorbate 60	Nonionic surfactant and emulsifier
Sorbitan monostearate	Co-emulsifier and interfacial stabilization
Propylene glycol	Humectant, solvent, and co-solvent
Purified water	Continuous aqueous phase
Container and propellant system	Aerosol generation and dose delivery

The listed excipient combination is characteristic of a fatty-alcohol-based aqueous emulsion. Cetyl alcohol and stearyl alcohol create the semi-solid structural network. Polysorbate 60 and sorbitan monostearate stabilize the oil-water interface. Propylene glycol improves wetting and may assist drug dispersion.

The commercial value of the excipient system is therefore linked to performance rather than ingredient novelty. A developer seeking a follow-on product would need to reproduce the critical quality attributes of the foam, not merely match the nominal inactive ingredient list.

What formulation attributes determine CORTIFOAM performance?

Four attributes are commercially important.

Foam expansion and collapse

The product must produce a consistent foam volume after actuation. Excessively stable foam may limit spreading and delay drug release. Foam that collapses too quickly may leak from the rectum before distributing across the target tissue.

Testing should measure:

• Initial foam density
• Expansion ratio
• Collapse time
• Drainage rate
• Bubble-size distribution
• Dose-to-dose variability
• Performance at different temperatures and orientations

A formulation with a narrower bubble-size distribution could improve dose reproducibility and mucosal coverage.

Rheology and retention

Rectal retention depends on yield stress, viscosity, adhesion, and melting behavior. The formulation must remain in place long enough to deliver hydrocortisone acetate while avoiding excessive bulk or discomfort.

The fatty-alcohol network can be adjusted through:

• Cetyl-to-stearyl alcohol ratio
• Total wax concentration
• Emulsifying wax level
• Surfactant balance
• Water content
• Propylene glycol concentration

These changes can alter foam strength, spreadability, and drug release. Small shifts in the emulsifier system may cause major changes in aerosol performance.

Drug dispersion

Hydrocortisone acetate is poorly water soluble. A commercial formulation therefore relies on suspension or finely dispersed drug within the emulsion system. Particle-size distribution, sedimentation, wetting, and redispersibility affect dose uniformity.

Key development controls include:

• Hydrocortisone acetate particle-size distribution
• Crystal form
• Milling or micronization conditions
• Wetting behavior
• Suspension uniformity
• Assay and content uniformity
• Chemical stability under propellant exposure

A reformulation that changes the drug’s particle size may alter both local release and comparative clinical performance.

Local tolerability

Rectal mucosa is sensitive to surfactants, preservatives, alcohols, pH extremes, and osmotic stress. Although CORTIFOAM is a short-course product, repeated daily use can amplify irritation.

A differentiated excipient strategy could reduce:

• Burning and stinging
• Dryness
• Tissue irritation
• Sensitization risk
• Residual foaming agent after administration

The most commercially attractive approach is usually excipient simplification rather than addition of multiple functional ingredients.

What excipient strategies could improve CORTIFOAM?

Strategy 1: Optimize the existing fatty-alcohol emulsion

The lowest regulatory-risk path is to preserve the established excipient architecture while optimizing ratios and processing conditions. This approach may improve foam consistency without creating a materially different product.

Potential benefits include:

• Lower development cost
• Easier bridging to historical product performance
• Reduced excipient qualification burden
• Familiar manufacturing equipment
• Lower clinical differentiation requirements

The main risk is that even a small change in surfactant or wax composition could affect bioavailability and therapeutic equivalence.

Strategy 2: Use a lower-irritancy surfactant system

Polysorbate 60 and sorbitan monostearate are established emulsifiers, but a developer could evaluate alternative nonionic surfactants or polymeric stabilizers. Candidates would need to remain compatible with rectal administration and the applicable FDA inactive-ingredient precedent.

Potential options include:

• Poloxamer systems
• Lecithin-based emulsification
• Alternative sorbitan esters
• Low-level cellulose or carbomer rheology modifiers
• Polyethylene glycol-based co-solvent systems

The opportunity is improved tolerability and a more modern excipient profile. The risk is reduced foam quality, altered drug release, or a need for additional clinical evidence.

Strategy 3: Develop a propellant-reduced or propellant-free delivery system

A metered pump, bag-on-valve system, or mechanically generated foam could reduce dependence on traditional aerosol propellants. The commercial rationale includes environmental positioning, packaging flexibility, and potential use in markets with restrictions on certain propellant classes.

The technical barriers are substantial:

• Reproducible metering
• Foam generation without pressurized propellant
• Product evacuation at low fill levels
• Microbial control
• Container compatibility
• User-dependent actuation force
• Equivalence to the reference foam

A propellant change is unlikely to qualify as a simple formulation substitution if it materially changes delivery dynamics.

Strategy 4: Improve mucosal residence time

A mucoadhesive system could increase residence time and reduce leakage. Possible approaches include low concentrations of carbomer, polycarbophil, cellulose derivatives, or thiolated polymers.

This strategy must avoid excessive viscosity. A rectal product that is difficult to expel, spreads poorly, or causes discomfort may lose practical adherence despite longer theoretical residence.

Strategy 5: Create a preservative-minimized product

The historical formulation does not identify a prominent preservative system in the principal inactive-ingredient list. A preservative-minimized or preservative-free product could have commercial value, particularly for patients with repeated exposure or sensitivity concerns.

The tradeoff is higher microbiological risk. The developer would need validated manufacturing controls, microbial limits, in-use stability data, and container-closure protection.

What patents protect CORTIFOAM and its formulation?

CORTIFOAM’s core commercial protection is unlikely to depend on a strong, unexpired composition-of-matter patent because hydrocortisone acetate is an established corticosteroid. Relevant rights are more likely to involve:

• Rectal foam composition
• Aerosol packaging
• Applicator geometry
• Metered-dose delivery
• Foam generation
• Manufacturing processes
• Specific treatment methods

The FDA Orange Book is the primary source for identifying patents listed against an approved drug application [2]. Historical product labeling identifies CORTIFOAM as an approved prescription product, but the commercial relevance of any formulation or delivery patents depends on their filing dates, terminal disclaimers, maintenance status, and expiration dates.

A follow-on developer should distinguish three categories:

IP category	Relevance to CORTIFOAM
Hydrocortisone acetate composition patents	Low practical relevance because the active ingredient is old
Foam formulation patents	Potential relevance if unexpired and listed or enforceable
Device and applicator patents	Material risk for aerosol or metered delivery products
Manufacturing patents	Potential barrier if process-specific and difficult to design around
Method-of-use patents	Narrower relevance for ulcerative proctitis treatment

The absence of a meaningful Orange Book patent barrier would not eliminate risk from unlisted device, formulation, or process patents. A freedom-to-operate review should cover U.S., European, Canadian, Australian, and major emerging-market patent families.

When does CORTIFOAM lose exclusivity?

CORTIFOAM’s active ingredient has long been off-patent. The relevant commercial question is not loss of molecule exclusivity but the availability of an approved generic or therapeutically equivalent rectal foam.

FDA approval of a generic would depend on the applicable abbreviated new drug application pathway, product-specific guidance, reference-product availability, and the ability to demonstrate pharmaceutical equivalence and bioequivalence or another FDA-accepted equivalence standard [3].

Key exclusivity variables include:

• NDA approval date
• Any remaining regulatory exclusivity
• Orange Book patent listings
• Reference-listed drug availability
• Generic product-specific guidance
• Paragraph IV certifications
• Litigation and settlement terms

Because CORTIFOAM is an old product, the practical barrier is likely development complexity rather than statutory exclusivity.

Which companies could challenge CORTIFOAM?

Potential challengers include generic manufacturers with experience in:

• Rectal dosage forms
• Topical corticosteroids
• Aerosol products
• Metered-dose packaging
• Complex generics
• Contract manufacturing of semisolid products

The strongest candidates are companies that already manufacture foam products or have access to aerosol filling and applicator assembly. A conventional oral-solid-dose generic manufacturer would face a steeper technical transition.

A Paragraph IV challenge would be relevant only if unexpired patents are listed in the Orange Book. If no enforceable Orange Book patents remain, a generic sponsor could pursue an ANDA without a Paragraph IV litigation strategy, subject to other certification requirements [2,3].

What is the FDA regulatory status of CORTIFOAM?

CORTIFOAM is associated with an FDA-approved hydrocortisone acetate rectal aerosol label for ulcerative proctitis [1]. The product’s regulatory classification is important because rectal foam is a complex dosage form. FDA review is likely to focus on:

• Active-ingredient identity and strength
• Foam dose delivery
• Applicator function
• Drug distribution
• Content uniformity
• Microbiological quality
• Stability
• Local tolerability
• Comparative performance against the reference product

A reformulated product with a new device, new excipient system, or materially altered release profile could require a 505(b)(2) application rather than a straightforward ANDA, depending on the degree of difference and the evidence package [4].

What generic entry risks exist for CORTIFOAM?

Generic entry risk is moderate from a technical perspective and potentially higher from a legal perspective if no active listed patents block approval.

The main entry barriers are:

1. Reproducing foam performance.
2. Matching dose delivery through the applicator.
3. Demonstrating content uniformity for a poorly water-soluble drug.
4. Establishing stability in the final container.
5. Securing a reliable aerosol or bag-on-valve manufacturing partner.
6. Managing device and packaging intellectual property.
7. Demonstrating acceptable local tolerability.

A generic may also face limited market scale. The product treats a localized indication, and market demand may be smaller than for oral or injectable corticosteroids. That can reduce the number of companies willing to fund complex product development.

What commercial opportunities exist beyond a generic CORTIFOAM?

Authorized generic or licensed supply

A manufacturer could pursue an authorized generic, contract supply arrangement, or regional license. This route would reduce formulation and regulatory risk if the brand owner controls an approved product and manufacturing process.

Reformulated rectal foam

A reformulated product could target:

• Improved retention
• Reduced leakage
• Lower-irritancy excipients
• Easier applicator use
• Smaller environmental footprint
• Preservative minimization

The commercial premium would depend on whether the improvement affects adherence, symptom control, or patient preference.

Combination or step-down therapy

A combination product with a locally acting anti-inflammatory or another established rectal therapy could address broader disease management. This approach would carry substantial clinical, regulatory, and patent complexity and would require a clear therapeutic rationale.

Platform technology

A stable rectal foam platform could be used for other locally acting drugs, including mesalamine, budesonide, anesthetics, or protective agents. Platform value would come from the device, foam-generation technology, and manufacturing process rather than from CORTIFOAM alone.

How strong is the CORTIFOAM patent estate?

The patent estate appears structurally weaker around the active ingredient and potentially stronger around formulation, aerosol delivery, and device implementation. Commercial strength should be assessed using a claim-by-claim framework:

Factor	Strategic assessment
Active-ingredient patents	Low strength because hydrocortisone acetate is established
Formulation claims	Potentially meaningful if they cover narrow excipient ratios or performance ranges
Device claims	Important for applicator and metered aerosol designs
Process claims	Relevant where scale-up depends on protected mixing or filling steps
Orange Book protection	Must be confirmed against the current approved application
Design-around potential	Likely moderate, depending on device and foam architecture
Biosimilar protection	Not relevant; CORTIFOAM is a small-molecule product

How does CORTIFOAM compare with competing rectal corticosteroids?

CORTIFOAM competes with hydrocortisone suppositories, hydrocortisone enemas, budesonide foam, and other rectal anti-inflammatory products.

Product type	Main advantage	Main limitation
Hydrocortisone rectal foam	Low-volume, broad mucosal coating	Foam and device complexity
Hydrocortisone suppository	Simple solid dosage form	More limited distribution
Hydrocortisone enema	Larger-area delivery	Higher volume and leakage burden
Budesonide foam	Strong local corticosteroid positioning	Higher formulation and regulatory competition
Mesalamine products	Nonsteroidal anti-inflammatory option	Different mechanism and tolerability profile

Budesonide foam is the closest technical comparator because it uses a rectal foam platform and competes for similar patients. A CORTIFOAM follow-on product would need either lower cost, easier administration, better retention, or a more favorable excipient and device profile.

Key Takeaways

• CORTIFOAM is a hydrocortisone acetate rectal foam for ulcerative proctitis.
• The principal excipient opportunity is optimization of the fatty-alcohol emulsion and surfactant system.
• Foam density, collapse time, rheology, drug dispersion, and applicator performance are critical quality attributes.
• Hydrocortisone acetate has limited active-ingredient patent value; formulation, device, and process patents are more relevant.
• Generic entry is constrained primarily by complex dosage-form development rather than the age of the active ingredient.
• A lower-irritancy, propellant-reduced, or more-retentive formulation could support differentiated commercial positioning.
• Biosimilar risk is not applicable because CORTIFOAM contains a small-molecule corticosteroid.
• The most credible commercial paths are a generic, authorized generic, licensed supply product, or improved rectal-foam platform.

FAQs

Is CORTIFOAM a biologic or biosimilar product?

No. CORTIFOAM contains hydrocortisone acetate, a small-molecule corticosteroid. The relevant FDA pathway is generally an ANDA or, for materially different products, a 505(b)(2) application.

Can CORTIFOAM be reformulated with different excipients?

Yes, but the regulatory consequences depend on the change. A minor excipient adjustment may support an ANDA if pharmaceutical equivalence and comparative performance are established. A new delivery system or materially altered release profile could require a 505(b)(2) application.

What is the most important excipient for CORTIFOAM foam quality?

No single excipient controls performance. The cetyl alcohol, stearyl alcohol, emulsifying wax, polysorbate 60, and sorbitan monostearate system collectively determines foam structure, emulsion stability, spreadability, and collapse behavior.

Does CORTIFOAM have biosimilar competition?

No. Biosimilar competition applies to biological products. CORTIFOAM faces generic and reformulation competition instead.

Is a propellant-free CORTIFOAM product commercially feasible?

It is technically feasible, but equivalence and usability would be difficult to establish. A propellant-free product would need reliable metering, reproducible foam generation, microbiological control, and comparable rectal distribution.

References

1. DailyMed. (n.d.). Cortifoam: Hydrocortisone acetate rectal aerosol, 10% prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.